Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Publication
, Journal Article
Erba, HP; Othus, M; Walter, RB; Kirschbaum, MH; Tallman, MS; Larson, RA; Slovak, ML; Kopecky, KJ; Gundacker, HM; Appelbaum, FR
Published in: Leuk Res
March 2014
We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (>50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1-21 or days 1-7 and 15-21, repeated every 28 days (4 treatment regimens). Responses were seen in all regimens, with overall response rate (CR + CRi + PR) highest (20%) among patients receiving tipifarnib 300 mg twice daily on days 1-21. Toxicities were acceptable. Unless predictors of response to tipifarnib are identified, further study as a single agent in this population is unwarranted.
Duke Scholars
Published In
Leuk Res
DOI
EISSN
1873-5835
Publication Date
March 2014
Volume
38
Issue
3
Start / End Page
329 / 333
Location
England
Related Subject Headings
- Treatment Outcome
- Survival Rate
- Remission Induction
- Quinolones
- Male
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Female
- Farnesyltranstransferase
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Othus, M., Walter, R. B., Kirschbaum, M. H., Tallman, M. S., Larson, R. A., … Appelbaum, F. R. (2014). Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res, 38(3), 329–333. https://doi.org/10.1016/j.leukres.2013.12.001
Erba, Harry P., Megan Othus, Roland B. Walter, Mark H. Kirschbaum, Martin S. Tallman, Richard A. Larson, Marilyn L. Slovak, Kenneth J. Kopecky, Holly M. Gundacker, and Frederick R. Appelbaum. “Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.” Leuk Res 38, no. 3 (March 2014): 329–33. https://doi.org/10.1016/j.leukres.2013.12.001.
Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, et al. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res. 2014 Mar;38(3):329–33.
Erba, Harry P., et al. “Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.” Leuk Res, vol. 38, no. 3, Mar. 2014, pp. 329–33. Pubmed, doi:10.1016/j.leukres.2013.12.001.
Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, Slovak ML, Kopecky KJ, Gundacker HM, Appelbaum FR. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res. 2014 Mar;38(3):329–333.
Published In
Leuk Res
DOI
EISSN
1873-5835
Publication Date
March 2014
Volume
38
Issue
3
Start / End Page
329 / 333
Location
England
Related Subject Headings
- Treatment Outcome
- Survival Rate
- Remission Induction
- Quinolones
- Male
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Female
- Farnesyltranstransferase